CD38 as a prognostic marker in chronic lymphocytic leukaemia at a single New Zealand centre: Patient survival in comparison to age- and sex-matched population data

Internal Medicine Journal

Volumn 40, Issue 12, 2010, Pages 842-849

  Hock, B D ^a   McKenzie, J L ^a   McArthur, L ^c   Tansley, S ^b   Taylor, K G ^a   Fernyhough, L J ^a,c,d  

^a Haematology Research Group   (New Zealand)

^b CHRISTCHURCH HOSPITAL   (New Zealand)

^c CANTERBURY HEALTH LABORATORIES   (New Zealand)

^d UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

Binet; CD38; CLL; Flow cytometry; Prognosis

Indexed keywords

CD38 ANTIGEN;

AGED; ARTICLE; CANCER STAGING; CHRONIC LYMPHATIC LEUKEMIA; DISEASE ASSOCIATION; FEMALE; FLOW CYTOMETRY; HUMAN; MAJOR CLINICAL STUDY; MALE; NEW ZEALAND; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL; TREATMENT FREE SURVIVAL;

ADOLESCENT; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ANTIGENS, CD38; BIOLOGICAL MARKERS; FEMALE; FOLLOW-UP STUDIES; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MIDDLE AGED; NEOPLASM STAGING; NEW ZEALAND; PROGNOSIS; SEX FACTORS; SURVIVAL RATE; YOUNG ADULT;

EID: 78650685288     PISSN: 14440903     EISSN: 14455994     Source Type: Journal    
DOI: 10.1111/j.1445-5994.2009.02135.x     Document Type: Article

References (18)

1. Keating MJ, Chiorazzi N, Messmer B, Damle RN, Allen SL, Rai KR et al. Biology and treatment of chronic lymphocytic leukemia. Hematology (Am Soc Hematol Educ Program) 2003; 153-75.
2. Van Bockstaele F, Verhasselt B, Philippe J. Prognostic markers in chronic lymphocytic leukemia: a comprehensive review. Blood Rev 2009; 23: 25-47.
3. Rassenti LZ, Jain S, Keating MJ, Wierda WG, Grever MR, Byrd JC et al. Relative value of ZAP-70, CD38, and immunoglobulin mutation status in predicting aggressive disease in chronic lymphocytic leukemia. Blood 2008; 112: 1923-30.
4. Hamblin TJ, Orchard JA, Ibbotson RE, Davis Z, Thomas PW, Stevenson FK et al. CD38 expression and immunoglobulin variable region mutations are independent prognostic variables in chronic lymphocytic leukemia, but CD38 expression may vary during the course of the disease. Blood 2002; 99: 1023-9.
5. Krober A, Seiler T, Benner A, Bullinger L, Bruckle E, Lichter P et al. V(H) mutation status, CD38 expression level, genomic aberrations, and survival in chronic lymphocytic leukemia. Blood 2002; 100: 1410-16.
6. Gentile M, Mauro FR, Calabrese E, De Propris MS, Giammartini E, Mancini F et al. The prognostic value of CD38 expression in chronic lymphocytic leukaemia patients studied prospectively at diagnosis: a single institute experience. Br J Haematol 2005; 130: 549-57.
7. Morilla A, Gonzalez de Castro D, Del Giudice I, Osuji N, Else M, Morilla R et al. Combinations of ZAP-70, CD38 and IGHV mutational status as predictors of time to first treatment in CLL. Leuk Lymphoma 2008; 49: 2108-15.
8. Boonstra JG, van Lom K, Langerak AW, Graveland WJ, Valk PJ, Kraan J et al. CD38 as a prognostic factor in B cell chronic lymphocytic leukaemia (B-CLL): comparison of three approaches to analyze its expression. Cytometry B Clin Cytom 2006; 70: 136-41.
9. Thornton PD, Fernandez C, Giustolisi GM, Morilla R, Atkinson S, A'Hern RP et al. CD38 expression as a prognostic indicator in chronic lymphocytic leukaemia. Hematol J 2004; 5: 145-51.
10. Ghia P, Guida G, Stella S, Gottardi D, Geuna M, Strola G et al. The pattern of CD38 expression defines a distinct subset of chronic lymphocytic leukemia (CLL) patients at risk of disease progression. Blood 2003; 101: 1262-9.
11. Catovsky D, Richards S, Matutes E, Oscier D, Dyer MJ, Bezares RF et al. Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial. Lancet 2007; 370: 230-9.
12. Thurmes P, Call T, Slager S, Zent C, Jenkins G, Schwager S et al. Comorbid conditions and survival in unselected, newly diagnosed patients with chronic lymphocytic leukemia. Leuk Lymphoma 2008; 49: 49-56.
13. Apelgren P, Hasselblom S, Werlenius O, Nilsson-Ehle H, Andersson PO. Evaluation of clinical staging in chronic lymphocytic leukemia- population-based study. Leuk Lymphoma 2006; 47: 2505-16.
14. Ries LAG, Krapcho M, Stinchcomb DG, Howlader N, Horner MJ, Mariotto A et al., eds. SEER Cancer Statistics Review, 1975-2005. Bethesda, MD: National Cancer Institute; 2008 [cited 2009 Mar 26]. Available from: URL: based on November 2007 SEER data submission, posted to the SEER web site, 2008.
15. Dighiero G, Maloum K, Desablens B, Cazin B, Navarro M, Leblay R et al. Chlorambucil in indolent chronic lymphocytic leukemia. French Cooperative Group on Chronic Lymphocytic Leukemia. N Engl J Med 1998; 338: 1506-14.
16. Molica S, Levato D. What is changing in the natural history of chronic lymphocytic leukemia? Haematologica 2001; 86: 8-12.
17. Hayat A, O'Brien D, O'Rourke P, McGuckin S, Fitzgerald T, Conneally E et al. CD38 expression level and pattern of expression remains a reliable and robust marker of progressive disease in chronic lymphocytic leukemia. Leuk Lymphoma 2006; 47: 2371-9.
18. Weinberg JB, Volkheimer AD, Chen Y, Beasley BE, Jiang N, Lanasa MC et al. Clinical and molecular predictors of disease severity and survival in chronic lymphocytic leukemia. Am J Hematol 2007; 82: 1063-70.